ASP Isotopes (NASDAQ:ASPI) Stock Price Down 7% - Should You Sell?

Key Points

• Shares fell about 7% to $7.88 on Monday on light trading (~1.96M shares, down 69% from the 6.38M average); the stock is trading below its 200‑day SMA ($8.44) but above its 50‑day SMA ($6.43).
• Analyst sentiment is mixed with a MarketBeat consensus of Hold and an average price target of $13, reflecting notable upside despite two Buy and one Sell rating.
• Fundamentals and insider activity are concerning: ASP reported an EPS miss (‑$0.15 vs. ‑$0.10) and a ~‑1,259% net margin, insiders have sold ~505,591 shares in the last 90 days, while institutional investors (16.8% ownership) have also been adding positions.

Shares of ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) were down 7% during trading on Monday . The company traded as low as $7.69 and last traded at $7.8830. Approximately 1,956,681 shares were traded during trading, a decline of 69% from the average daily volume of 6,384,147 shares. The stock had previously closed at $8.48.

Wall Street Analyst Weigh In

ASPI has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on shares of ASP Isotopes in a research report on Thursday, December 4th. They set an "overweight" rating and a $13.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, December 29th. Canaccord Genuity Group reissued a "buy" rating and set a $11.00 price target on shares of ASP Isotopes in a report on Monday, November 24th. Finally, Loop Capital set a $15.00 price objective on ASP Isotopes in a research note on Monday, October 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $13.00.

ASP Isotopes Stock Performance

The company has a market capitalization of $830.30 million, a P/E ratio of -5.76 and a beta of 3.47. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. The business's fifty day simple moving average is $6.43 and its 200-day simple moving average is $8.44.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.05). The firm had revenue of $4.89 million for the quarter, compared to analysts' expectations of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. As a group, equities analysts anticipate that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, Chairman Paul Elliot Mann sold 162,153 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $5.75, for a total transaction of $932,379.75. Following the completion of the transaction, the chairman owned 7,759,538 shares in the company, valued at $44,617,343.50. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Heather Kiessling sold 80,000 shares of ASP Isotopes stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total transaction of $464,000.00. Following the completion of the transaction, the chief financial officer directly owned 732,500 shares of the company's stock, valued at $4,248,500. The trade was a 9.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 505,591 shares of company stock valued at $3,233,245 in the last ninety days. Corporate insiders own 14.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Rovida Advisors Inc. bought a new stake in ASP Isotopes during the second quarter worth approximately $16,148,000. Rovida Investment Management Ltd boosted its holdings in shares of ASP Isotopes by 528.6% in the 2nd quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock worth $16,148,000 after purchasing an additional 1,850,000 shares during the period. Marshall Wace LLP increased its position in shares of ASP Isotopes by 3,669.1% during the 3rd quarter. Marshall Wace LLP now owns 1,279,121 shares of the company's stock valued at $12,305,000 after purchasing an additional 1,245,184 shares during the last quarter. Vanguard Group Inc. increased its position in shares of ASP Isotopes by 37.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock valued at $43,451,000 after purchasing an additional 1,241,024 shares during the last quarter. Finally, Jump Financial LLC purchased a new position in ASP Isotopes during the third quarter worth $8,990,000. Institutional investors own 16.80% of the company's stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.